Skip to main content

Table 3 Response to therapy and patient’s outcome in all AML cases

From: The prognostic impact of Wilms tumor-1 polymorphism (rs16754) and human myeloid inhibitory C-type lectin-like receptor expression in cytogenetically normal-acute myeloid leukemia

Parameters

AML cases (N = 63)

Outcome

N (%)

Response at 28 days:

Died

17 (27.0)

CR

20 (31.7)

PR

26 (41.3)

Response at 6 months:

Died

26 (41.3 )

Relapse

11 (17.4)

CR

26 (41.3)

Response at 24 months

Died or relapse

37 (58.7)

CR

26 (41.3)

  1. CR complete remission, PR partial remission